Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
Chemotherapy Triplet Elicits Encouraging Activity in Pancreatic Adenocarcinoma
October 17th 2019The addition of cisplatin to gemcitabine and nab-paclitaxel resulted in encouraging activity in patients with previously untreated advanced pancreatic cancer, despite not having demonstrated the prespecified number of complete responses to meet the primary endpoint of a phase Ib/II clinical trial (NCT01893801), according to findings published in JAMA Oncology.
Read More
Safety Analysis Supports Adjuvant T-DM1 Use in Early HER2+ Breast Cancer
October 14th 2019Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.
Read More
Improving CAR T-Cell Therapies With Greater Understanding of Cancer Immunology
October 8th 2019Eduardo Sotomayor, MD, discusses the evolution of CAR T-cell therapy, adverse events that require careful monitoring, and novel strategies under development that may mitigate toxicity and improve T-cell persistence.
Read More
Amplifying Responses With ADCs and Checkpoint Inhibitors in Hodgkin Lymphoma
September 25th 2019Matthew G. Mei, MD, discusses current considerations in the frontline management of advanced-stage Hodgkin lymphoma as well as ongoing investigations with checkpoint inhibitors and cellular-based therapy.
Read More
Risk Patterns Prior to Progression From MGUS to Myeloma Call for Annual Assessments
September 20th 2019Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.
Read More
Subset of BRAF non-V600-Mutant mCRC Is Potentially More Sensitive to Anti-EGFR Therapy
September 18th 2019Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.
Read More
Tumor Biology Drives Personalized Surgical Interventions in Breast Cancer
September 17th 2019Shubhada Dhage, MD, FACS, discusses the role of surgery and other therapeutic modalities in breast cancer and explained the shift toward de-escalated treatments and less morbid surgical management strategies.
Read More
Lyman Shares Blueprint for Boosting Biosimilar Uptake in Oncology
September 16th 2019Gary H. Lyman, MD, MPH, discusses the current parameters used to develop a biosimilar, the impact these products have had in the treatment and supportive care settings, and ongoing initiatives to address remaining challenges.
Read More